Mucormicosis pulmonar asociada a sars-cov-2

Abstract

The invasive fungal infection caused by fungi in the order Mucorales is known as mucormycosis. This disease has become a global concern due to its high mortality and morbidity rates, especially in the context of the COVID-19 pandemic. The review focuses on the incidence, pathophysiology, and risk factors of the disease, as well as current diagnostic procedures. The need for more specific and cost-effective assays, such as those based on PCR and monoclonal antibodies, for effective diagnosis is suggested. The review also addresses current treatment options, including antifungal drug therapies, adjuvants, and surgical debridement, as well as the importance of nutraceutical-based therapy. In addition, the need to explore new treatment options, such as antibody-based therapy, cytokines, and combined/synergistic antifungal therapy, is highlighted. The review also points out current research gaps and the need to develop future studies in the field of COVID-19-associated pulmonary mucormycosis